View Future GrowthThis company listing is no longer activeThis company may still be operating, however this listing is no longer active. Find out why through their latest events.See Latest EventsNeuropathix 過去の業績過去 基準チェック /06Neuropathixの過去数年間の業績に関するデータが不十分です。主要情報n/a収益成長率n/aEPS成長率Pharmaceuticals 業界の成長5.95%収益成長率n/a株主資本利益率n/aネット・マージンn/a前回の決算情報31 Mar 2022最近の業績更新更新なしすべての更新を表示Recent updatesお知らせ • Aug 13Neuropathix, Inc. announced delayed 10-Q filingOn 08/12/2022, Neuropathix, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.お知らせ • May 17Neuropathix, Inc. announced delayed 10-Q filingOn 05/16/2022, Neuropathix, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.お知らせ • Apr 01Neuropathix, Inc. announced delayed annual 10-K filingOn 03/31/2022, Neuropathix, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.お知らせ • Jan 13Neuropathix, Inc. Appoints Daniel Richman to Board of AdvisorsNeuropathix, Inc. announced that it has appointed pain management expert Dr. Daniel Richman to the Company’s Board of Advisors. Dr. Richman is a world-renowned, board-certified attending anesthesiologist and pain management physician. Since 1991, Dr. Richman has been in practice at Hospital for Special Surgery (HSS) in the Department of Anesthesiology, Critical Care and Pain Management. Dr. Richman is also an assistant attending and clinical instructor within the Tri-Institutional Pain Management Fellowship in conjunction with New York-Presbyterian Hospital and Memorial Sloan Kettering Cancer Center. For the past 15 years, Dr. Richman has consistently been rated among Castle Connolly Top Doctors as an expert in pain management in the New York City metropolitan area. Additionally, Dr. Richman specializes in orthopedic-related pain management with a specific interest in managing conditions related to the cervical, thoracic and lumbar spine. He is an expert in interventional treatments such as epidural steroid injections, diagnostic nerve blocks both under fluoroscopic and ultrasound guidance, radiofrequency denervation, sympathetic blockade and discography. Dr. Richman has extensive knowledge of managing advanced pain with implantable technology such as intrathecal pumps and spinal cord stimulators. His positive experience in prescribing medical cannabis for difficult neuropathic pain spurred his interest in exploring more extensive cannabidiol (CBD) applications for nerve pain.お知らせ • Sep 18Kannalife, Inc. Appoints Tage Honoré as the Chairman of the Company’s Board of AdvisorsKannalife, Inc. announced that it has appointed pharmaceutical and biotechnology industry veteran Dr. Tage Honoré as the Chairman of the Company’s Board of Advisors. Dr. Honoré is a world-renowned pharma and biotechnology executive, entrepreneur, and pioneer with expert knowledge in the fields of Alzheimer’s disease, amyotrophic lateral sclerosis (ALS), anxiety, cancer immunotherapy, chronic pain, depression, epilepsy, female hormone replacement therapy (HRT), learning disorders, osteoporosis, Parkinson’s disease, stroke, and schizophrenia. Among his many accomplishments is the discovery of the AMPA subtype of excitatory amino acid receptors, as well as the AMPA antagonists CNQX and NBQX, which have been key tools for mapping the excitatory pathways in the central nervous system (CNS). Additionally, Dr. Honoré has published more than 100 scientific papers, is the inventor on 23 patents, and has championed 40 drugs to progress from idea to clinical development, including Gabatril (tiagabine) and other novel compounds that entered the prescription drug market. The organizational models Dr. Honoré developed to obtain record pipeline productivity in several companies are key to his business achievements. He has held several positions, including: VP Drug Discovery at Novo Nordisk A/S; Senior Executive VP Nervous System Research at Novartis Pharma Inc; VP Discovery Research at Purdue Pharma LP; and President and CEO at Aestus Therapeutics Inc. Dr. Honoré has a master’s degree in pharmaceutical science and doctoral degrees in medicinal chemistry and neurobiology. He also has business training from Harvard Business School and European Management Centre.収支内訳Neuropathix の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。収益と収入の歴史OTCPK:NPTX 収益、費用、利益 ( )USD Millions日付収益収益G+A経費研究開発費31 Mar 220-42031 Dec 210-43030 Sep 210-43030 Jun 210-43031 Mar 210-64031 Dec 200-53030 Sep 200-43030 Jun 200-43031 Mar 200-32031 Dec 190-32030 Sep 190-42030 Jun 190-42031 Mar 19001031 Dec 18011030 Sep 18011031 Dec 170-210質の高い収益: NPTXが 高品質の収益 を有しているかどうかを判断するにはデータが不十分です。利益率の向上: NPTXの 利益率 が過去 1 年間で改善したかどうかを判断するにはデータが不十分です。フリー・キャッシュフローと収益の比較過去の収益成長分析収益動向: NPTXの過去 5 年間の前年比収益成長率がプラスであったかどうかを判断するにはデータが不十分です。成長の加速: NPTXの過去 1 年間の収益成長を 5 年間の平均と比較するにはデータが不十分です。収益対業界: NPTXの過去 1 年間の収益成長がPharmaceuticals業界平均を上回ったかどうかを判断するにはデータが不十分です。株主資本利益率高いROE: NPTXは現在利益が出ていないため、自己資本利益率 ( 0% ) はマイナスです。総資産利益率使用総資本利益率過去の好業績企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 、過去の業績が好調な企業。View Financial Health企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2023/10/22 23:35終値2023/10/19 00:00収益2022/03/31年間収益2021/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Neuropathix, Inc. これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
お知らせ • Aug 13Neuropathix, Inc. announced delayed 10-Q filingOn 08/12/2022, Neuropathix, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
お知らせ • May 17Neuropathix, Inc. announced delayed 10-Q filingOn 05/16/2022, Neuropathix, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
お知らせ • Apr 01Neuropathix, Inc. announced delayed annual 10-K filingOn 03/31/2022, Neuropathix, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.
お知らせ • Jan 13Neuropathix, Inc. Appoints Daniel Richman to Board of AdvisorsNeuropathix, Inc. announced that it has appointed pain management expert Dr. Daniel Richman to the Company’s Board of Advisors. Dr. Richman is a world-renowned, board-certified attending anesthesiologist and pain management physician. Since 1991, Dr. Richman has been in practice at Hospital for Special Surgery (HSS) in the Department of Anesthesiology, Critical Care and Pain Management. Dr. Richman is also an assistant attending and clinical instructor within the Tri-Institutional Pain Management Fellowship in conjunction with New York-Presbyterian Hospital and Memorial Sloan Kettering Cancer Center. For the past 15 years, Dr. Richman has consistently been rated among Castle Connolly Top Doctors as an expert in pain management in the New York City metropolitan area. Additionally, Dr. Richman specializes in orthopedic-related pain management with a specific interest in managing conditions related to the cervical, thoracic and lumbar spine. He is an expert in interventional treatments such as epidural steroid injections, diagnostic nerve blocks both under fluoroscopic and ultrasound guidance, radiofrequency denervation, sympathetic blockade and discography. Dr. Richman has extensive knowledge of managing advanced pain with implantable technology such as intrathecal pumps and spinal cord stimulators. His positive experience in prescribing medical cannabis for difficult neuropathic pain spurred his interest in exploring more extensive cannabidiol (CBD) applications for nerve pain.
お知らせ • Sep 18Kannalife, Inc. Appoints Tage Honoré as the Chairman of the Company’s Board of AdvisorsKannalife, Inc. announced that it has appointed pharmaceutical and biotechnology industry veteran Dr. Tage Honoré as the Chairman of the Company’s Board of Advisors. Dr. Honoré is a world-renowned pharma and biotechnology executive, entrepreneur, and pioneer with expert knowledge in the fields of Alzheimer’s disease, amyotrophic lateral sclerosis (ALS), anxiety, cancer immunotherapy, chronic pain, depression, epilepsy, female hormone replacement therapy (HRT), learning disorders, osteoporosis, Parkinson’s disease, stroke, and schizophrenia. Among his many accomplishments is the discovery of the AMPA subtype of excitatory amino acid receptors, as well as the AMPA antagonists CNQX and NBQX, which have been key tools for mapping the excitatory pathways in the central nervous system (CNS). Additionally, Dr. Honoré has published more than 100 scientific papers, is the inventor on 23 patents, and has championed 40 drugs to progress from idea to clinical development, including Gabatril (tiagabine) and other novel compounds that entered the prescription drug market. The organizational models Dr. Honoré developed to obtain record pipeline productivity in several companies are key to his business achievements. He has held several positions, including: VP Drug Discovery at Novo Nordisk A/S; Senior Executive VP Nervous System Research at Novartis Pharma Inc; VP Discovery Research at Purdue Pharma LP; and President and CEO at Aestus Therapeutics Inc. Dr. Honoré has a master’s degree in pharmaceutical science and doctoral degrees in medicinal chemistry and neurobiology. He also has business training from Harvard Business School and European Management Centre.